Personal Finance

Moderna Stock Upgraded After Miserable 2023. Why This Year Could Be Better.

Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.

Continue reading this article with a Barron’s subscription.

View Options

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button